Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.72 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.72 |
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | PGK1 | P00558 | 1/20 | 0.60 |
| ▸ | PGK2 | P07205 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | NT5E | P21589 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2219631 | 0.89 | ADORA2A (0.71) | ADORA2AADORA2BSLC29A1CYP2C19ADORA3 | |
| SCHEMBL2218888 | 0.89 | ADORA2A (0.70) | ADORA2AADORA2BSLC29A1CYP2C19ADORA3 | |
| Nelarabine SCHEMBL9937290 | 0.87 | CYP2C19 (0.71) | ADORA2AADORA2BSLC29A1CYP2C19ADORA3 | |
| Nelarabine SCHEMBL20769831 | 0.87 | CYP2C19 (0.71) | ADORA2AADORA2BSLC29A1CYP2C19ADORA3 | |
| Nelarabine SCHEMBL14031852 | 0.87 | CYP2C19 (0.71) | ADORA2AADORA2BSLC29A1CYP2C19ADORA3 | |
| Nelarabine SCHEMBL2143756 | 0.87 | CYP2C19 (0.71) | ADORA2AADORA2BSLC29A1CYP2C19ADORA3 | |
| Nelarabine SCHEMBL18820 | 0.87 | CYP2C19 (0.71) | ADORA2AADORA2BSLC29A1CYP2C19ADORA3 | |
| Nelarabine SCHEMBL13575801 | 0.87 | CYP2C19 (0.71) | ADORA2AADORA2BSLC29A1CYP2C19ADORA3 | |
| Nelarabine SCHEMBL1818971 | 0.87 | CYP2C19 (0.71) | ADORA2AADORA2BSLC29A1CYP2C19ADORA3 | |
| Nelarabine SCHEMBL18321891 | 0.87 | CYP2C19 (0.71) | ADORA2AADORA2BSLC29A1CYP2C19ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040241706-A1 | Highly specific modulators of GTPases for target validation | IRM, LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040241706-A1 | Highly specific modulators of GTPases for target validation | CDC42, ARHGDIB, ARHGEF2 | ADORA2A 4341/4885ADORA2B 4641/4885SLC29A1 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.